The governments of the United States, the European Commission, Japan, Switzerland, Australia, New Zealand, South Korea, Canada, and Mexico are negotiating a trade agreement named the Anti-Counterfeiting Trade Agreement (ACTA). Despite the name, the agreement is designed to address not… Continue Reading
KEI publishes research and commentary in a variety of journals, periodicals, books and other independent publishing platforms. In-house, KEI presents information in blogs, correspondence and reports, as well as in occasional KEI research notes and papers. Timelines (several) Timelines regarding… Continue Reading
Below are a few links to pages that show our work in specific fields (note: this list is currently under construction and will be continually updated): Innovation and access to medical technologies Cancer Drugs Coronavirus/COVID-19 Orphan/Rare diseases A standalone page… Continue Reading
For more information, contact: (U.S.) James Love, KEI: james.love@keionline.org or +1 (202) 332-2670 (Chile) Luis Villaroel, Innovarte: info@innovarte.cl or +56 9 9827 9673 Chile FAQ What is happening in Chile with regard to HCV medicines and Xtandi, for prostate cancer?… Continue Reading
On Friday, 20 October 2017, India delivered the following intervention on compulsory licensing. India briefly recounted the experiences of Brazil, South Africa, and Thailand in using compulsory licensing to secure access to ARVs.
On October 13, 2017, KEI submitted comments to the WHO regarding the Draft Concept Note towards the WHO’s 13th General Programme of Work. The Draft Concept Note is available here: http://www.who.int/about/draft-concept-note_13th-programme-work.pdf
The text of KEI’s comments follow below, and a PDF is available here.
Friday, 13 October 2017
Dear Dr. Tedros,
On Wednesday, 4 October 2017, Knowledge Ecology International (KEI) delivered the following statement at the WIPO General Assembly during discussions on the Report of the Standing Committee on the Law of Patents (SCP).
WIPO General Assembly 2017 – Statement of KEI on the Report on the Standing Committee on the Law of Patents (SCP)
4 October 2017
Agenda item: 14. Report on the Standing Committee on the Law of Patents (SCP)
These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation.
My name is James Love. I work for Knowledge Ecology International, an NGO that focuses on the social aspects to the production, management and control of knowledge goods. I am also a member of the board of directors of the Union for Affordable Cancer Treatment.
The IP Chapter is complex, and in the time allocated, I will discuss five issues.
On July 11, 2017, the German Federal Supreme Court announced that it had affirmed the decision of the Federal Patent Court last year to issue a compulsory license allowing Merck to continue selling its HIV drug, raltegravir (marketed as Isentress).
Today at WIPO, KEI hosted a side event to discuss the ability of countries to deny injunctions in patent infringement cases.